Gilead Sciences (Mexico) Performance
| GILD Stock | MXN 1,870 0.00 0.00% |
On a scale of 0 to 100, Gilead Sciences holds a performance score of 13. The company retains a Market Volatility (i.e., Beta) of -0.32, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Gilead Sciences are expected to decrease at a much lower rate. During the bear market, Gilead Sciences is likely to outperform the market. Please check Gilead Sciences' variance, jensen alpha, sortino ratio, as well as the relationship between the information ratio and total risk alpha , to make a quick decision on whether Gilead Sciences' current trending patterns will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Gilead Sciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 5.3 B |
Gilead |
Gilead Sciences Relative Risk vs. Return Landscape
If you would invest 161,627 in Gilead Sciences on September 30, 2024 and sell it today you would earn a total of 25,373 from holding Gilead Sciences or generate 15.7% return on investment over 90 days. Gilead Sciences is generating 0.2495% of daily returns and assumes 1.4373% volatility on return distribution over the 90 days horizon. Simply put, 12% of stocks are less volatile than Gilead, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Gilead Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Gilead Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Gilead Sciences, and traders can use it to determine the average amount a Gilead Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1736
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GILD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.44 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Gilead Sciences is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Gilead Sciences by adding it to a well-diversified portfolio.
Gilead Sciences Fundamentals Growth
Gilead Stock prices reflect investors' perceptions of the future prospects and financial health of Gilead Sciences, and Gilead Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gilead Stock performance.
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 2.55 T | |||
| Shares Outstanding | 1.25 B | |||
| Price To Earning | 282.94 X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 79.06 X | |||
| Revenue | 27.28 B | |||
| EBITDA | 6.75 B | |||
| Cash And Equivalents | 29.01 B | |||
| Cash Per Share | 22.81 X | |||
| Total Debt | 25.18 B | |||
| Debt To Equity | 122.50 % | |||
| Book Value Per Share | 17.01 X | |||
| Cash Flow From Operations | 9.07 B | |||
| Earnings Per Share | 68.39 X | |||
| Total Asset | 63.17 B | |||
About Gilead Sciences Performance
Evaluating Gilead Sciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Gilead Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Gilead Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD SCIENCES operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 11000 people.Things to note about Gilead Sciences performance evaluation
Checking the ongoing alerts about Gilead Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gilead Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Gilead Sciences has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Over 84.0% of the company shares are owned by institutional investors |
- Analyzing Gilead Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gilead Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Gilead Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gilead Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gilead Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gilead Sciences' stock. These opinions can provide insight into Gilead Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Gilead Stock Analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.